Blue Sail Medical has acquired acquire all shares of New Valve Technology (NVT), and that the offer was accepted by the shareholders of NVT. The deal was publicly announced on the Chinese Stock Exchange the same day, and will leverage the capabilities and experience in interventional cardiology of its subsidiary, Biosensors International Group. Financial terms were not disclosed. NVT is a technology driven company dedicated to Transcatheter Aortic Valve Implantation (TAVI), with strong R&D pipeline and manufacturing capabilities based in Germany. "Biosensors is strategically positioned to accelerate the adoption of our products through its highly complementary and global direct sales force focused on interventional cardiology. This will help NVT to gain share in the TAVI market. We believe Biosensors will drive the growth of our existing business, expand into new geographies such as China, a market with enormous growth potential, and also help accelerate our R&D initiatives." Mr Urs Christen, NVT President and CEO.